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Abstract:  Epidemiologic data indicate that chronic obstructive pulmonary disease (COPD) is a leading cause of 
morbidity and mortality. Patients with poorly managed COPD are likely to experience exacerbations that require 
emergency department visits or hospitalization—two important drivers contributing to escalating healthcare resource use 
and costs associated with the disease. Exacerbations also contribute to worsening lung function and negative outcomes in 
COPD. The aim of this review is to present the perspective of nurse practitioners and physician assistants in terms of 
providing the pharmacologic and non-pharmacologic modalities needed to treat current and prevent future exacerbations. 
Major respiratory guidelines recommend treatment of acute exacerbations with short-acting bronchodilators, oral 
corticosteroids and antibiotics, as appropriate. Supplementary oxygen and/or ventilatory support may also be beneficial to 
selected patients. Treatments to minimize the risk of future exacerbations should include maintenance pharmacotherapies, 
risk-reduction measures (e.g. smoking cessation, influenza and pneumonia vaccinations), pulmonary rehabilitation, self-
management support and follow-up care. 
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INTRODUCTION 
  The 2010 Year of the Lung Declaration [1] made by the 
Forum of International Respiratory Societies was designed to 
increase awareness and action on respiratory conditions, 
including chronic obstructive pulmonary disease (COPD). 
Without interventions to cut risks, deaths from this widely 
prevalent, underdiagnosed, preventable and treatable condition 
(caused mainly by smoking and possibly less well-recognized 
risk factors) are projected to increase by more than 30% over 
the next decade [2-4]. The increasing airway obstruction, lung 
hyperinflation and physical activity limitations characteristic 
of stable disease progression are attributed primarily to a 
heterogeneous mixture of lung-structural abnormalities that 
may vary among individuals [5]. Exacerbations or worsening 
of symptoms, such as chronic cough, sputum production and 
dyspnea, punctuate the natural history of COPD and account 
for most of the health and financial burden associated with this 
disease [6]. These costs have been estimated to be as high as 
US$7,757 per exacerbation [7], with the largest component of 
the total costs of COPD exacerbations typically resulting from 
hospitalization. Although the costs can vary, they are 
associated with the severity of the exacerbation. Indirect costs 
have rarely been measured, but these resource-associated 
financial consequences of COPD exacerbations are likely to 
contribute substantially to overall costs. In addition, mortality 
rates are high, reaching 40% at one year in those individuals 
needing ventilatory support and up to 49% by three years 
following hospitalization for an acute exacerbation [5]. 
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  Evidence from the literature suggests that there is a high-
risk, eight-week window of possible recurrence following an 
initial exacerbation [8] and a high-risk subpopulation who 
experience frequent exacerbations (6-month intervals; >3-
per year) [9]. Results from the Evaluation of COPD 
Longitudinally to Identify Predictive Surrogate Endpoints 
(ECLIPSE) [10] study suggest that there is a frequent-
exacerbation phenotype of COPD that is independent of 
disease severity. These patients have faster lung function 
decline and worse health-related quality of life compared 
with patients who have infrequent exacerbations [9]. Overall, 
the classic view of exacerbations as random events has been 
replaced by the recognition that the future risk of an 
exacerbation can be correlated to a history of past 
exacerbations [6]. In addition, the likelihood of a second 
event may be related to therapy used for an initial 
exacerbation [11] or non-resolution of the systemic 
inflammatory response [12]. Acute exacerbations occur more 
often in winter [13, 14] and accelerate disease progression 
[6]. 
  The increasing presence of physician assistants (PAs) and 
nurse practitioners (NPs) in medical specialty, internal 
medicine and underserved settings [15] makes it likely that 
these healthcare providers will serve as important contacts 
for patients experiencing exacerbations. In an era where 
medicine requires collaborative multidisciplinary problem-
solving to deliver affordable, quality care, it is important that 
all healthcare providers, including NPs and PAs, effectively 
manage patients with COPD during chronic, stable periods 
and accurately diagnose and treat acute exacerbations to 
improve patient outcomes. Recent reports have highlighted 
the important role of nurse-led management programs in 
improving patient outcomes [16-19]. This review focuses on 
interventions in outpatient and inpatient settings and 14    The Open Nursing Journal, 2012, Volume 6  Garvey and Ortiz 
addresses important areas where healthcare providers can 
play a role in preventing or delaying exacerbation recurrence. 
DEFINITION 
  There is no clear consensus on the definition of COPD 
exacerbations across all settings as a result of the wide 
heterogeneity of clinical presentation and disease 
progression [20], although exacerbations can be stratified as 
mild, moderate, or severe according to the symptomatic 
criteria first proposed by Anthonisen et al., in 1987 [21]. 
These criteria by 1 of 3 symptoms: increased breathlessness; 
increased sputum volume; new or increased sputum 
purulence, are divided into mild (1 symptom), moderate (2 
symptoms) and severe (1 symptom with at least 1 additional 
feature, including: upper respiratory tract infection in the 
previous 5 days, fever without other cause, increased 
wheezing or cough, or a 20% increase in respiratory or heart 
rate compared with baseline). 
  Cross-study differences in exacerbations reflect to some 
extent the differences in definitions used and classifications 
of these events [5, 22, 23]. In general, symptom- or 
healthcare utilization–based definitions are used. A 
symptom-based definition which is widely accepted and 
incorporated into key guidelines (e.g. Global Initiative for 
Chronic Obstructive Lung Disease [GOLD] [5] and 
American Thoracic Society/European Respiratory Society 
[ATS/ERS] [22]) is “an event in the natural course of the 
disease characterized by a change in the patient’s baseline 
dyspnea, cough and/or sputum that is beyond normal day-to-
day variations, is acute in onset and may warrant a change in 
regular medication in a patient with underlying COPD”[5]. 
Healthcare utilization–defined exacerbations, such as any 
hospital admission with a primary diagnosis of COPD 
including those related to COPD, bronchitis or (in some 
cases) asthma by any physician in emergency departments, 
offices or hospital, can be treated as one episode if the 
interval between adjacent contacts is less than 14 days [24]. 
Such definitions have been used as a clinical endpoint in 
some major trials [23], since, in the absence of daily diaries 
to record symptoms, they are more readily recalled. 
  The GOLD guidelines [5] focus on appropriate antibiotic 
selection in further classifying exacerbations, whereas 
ATS/ERS [22] stratifies exacerbations according to the need 
for healthcare utilization. A composite system for ranking 
exacerbations according to their degree of severity is shown 
in Fig. (1) [5, 21, 22]. 
  The lack of consensus means that NPs and PAs, as well 
as physicians, working in primary care report lack of 
awareness and use of COPD guidelines, and also feel a need 
for correct information related to epidemiology of the 
condition and the different benefits of available treatment 
strategies [25]. 
ETIOLOGY 
  Respiratory infections are associated with the majority of 
COPD exacerbations and their severity [26], including viral 
(Rhinovirus spp., influenza) and/or bacterial (Haemophilus 
influenzae, Streptococcus pneumoniae, Moraxella 
catarrhalis, Enterobacteriaceae spp., Pseudomonas spp.) 
infections of the tracheobronchial tree. However, a clinically 
significant number of exacerbations occur without the 
presence of detectable infection [26]. Furthermore, most 
patients have evidence of bacterial colonization, and 
potentially pathogenic organisms can be recovered from the 
respiratory tract secretions of virtually all patients with 
COPD [27]. Non-microbiologic causes include 
environmental irritants and lack of adherence to prescribed 
treatments, including medications and oxygen therapy, and 
failure to participate in pulmonary rehabilitation (PR) [22]. 
Oxidative stress may be an important mechanism that 
contributes to the amplified inflammatory response 
characteristic of COPD exacerbations [5]. 
  Exacerbation frequency may be independently associated 
 
1Increase in dyspnea/change in sputum volume/change in sputum purulence; in addition to these symptoms, the presence of comorbidities (e.g. congestive heart 
failure, coronary artery disease, chronic renal or liver failure) is a risk factor for relapse. 
ED=emergency department; FEV1=forced expiratory volume in 1 second. 
aPlease refer to references [5, 21, 22] as cited in text. 
Fig. (1). Ranking of COPD exacerbations and risk factors for relapse.
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with progression of disease, a history of exacerbations, 
poorer health related-quality of life, elevated white blood cell 
counts and a history of heartburn [10]. Understanding the 
mechanism underlying exacerbation frequency may lead to 
improved preventive therapies. 
DIAGNOSIS 
  The lack of an agreed upon (or consensus) classification 
as to COPD exacerbations, and signs and symptoms 
common to other conditions, complicates diagnosis. 
Differential diagnosis is thus important to correctly identify 
an exacerbation of COPD in respect of possibly confounding 
history and physical signs. Radiography can assist in ruling 
out pneumonia and pneumothorax, while electrocardio-
graphy is useful to eliminate diagnosis of right ventricular 
hypertrophy, arrhythmia, or ischemia [5]. 
  However, in regular practice, NPs and PAs can play a 
leading role by administering screening questionnaires at 
presentation. These should be used routinely to assess risk 
factors and medical history, including genetic predisposition 
to underlying COPD [28]. The ATS/ERS guidelines suggest 
a number of elements to assist in the evaluation and 
diagnosis of exacerbations, based on clinical history, 
physical findings, and laboratory diagnostic procedures [17]. 
In addition, the GOLD guidelines recommend monitoring 
symptom patterns and appropriateness of current 
pharmacologic treatments. Symptom patterns of particular 
importance are increased dyspnea and more “winter colds,” 
prior exacerbation or respiratory disorder–related 
hospitalization, and presence of comorbidities that may 
restrict activity [5].
 
  Measurement of arterial blood gases is important in 
determining the severity of an exacerbation [5]. This can be 
enhanced by monitoring blood oxygenation via  pulse 
oximetry, with change from baseline established by prior 
lung function and laboratory tests in patients known to have 
COPD, and assessing severity of symptoms (e.g. change in 
sputum volume or color, use of accessory respiratory 
muscles, paradoxical chest wall movements, onset of 
peripheral edema, somnolence, cyanosis and signs of right 
heart failure) in patients experiencing exacerbations [5]. 
Although spirometry is recommended to diagnose and stage 
stable COPD cases (Table 1) [5], pulmonary function testing 
is not recommended for patients in the midst of an 
exacerbation, as it shows only a weak correlation with 
arterial blood gases. 
  Specific systemic biomarkers are beginning to be 
identified in association with exacerbations and their 
recurrence; for example, patients who experience frequent 
exacerbations have been found to have significantly higher 
levels of serum IL-6 and C-reactive protein (CRP) during 
their recovery period after an exacerbation, and high serum 
CRP concentrations measured 14 days after an index 
exacerbation can predict recurrent exacerbations within 50 
days [12].
 Other known risk factors for relapse are listed in 
Fig. (1) [5, 21, 22]. 
Treatment 
  Nurse practitioners and PAs should work collaboratively 
with the healthcare team, patient and family members to 
achieve evidence based, short and long term outcomes in 
patients with COPD including prevention and early and 
effective management of exacerbations. A treatment 
algorithm encompassing pharmacologic and non-
pharmacologic strategies is presented in Fig. (2) [29]. Milder 
exacerbations may respond to an increase in the dose and/or 
frequency of existing bronchodilator therapy [5]. It is 
important to emphasize that exacerbation severity does not 
always equal severity of the underlying disease (e.g. 
individuals with mild COPD may experience an acute 
sentinel event whereas the opposite may be true for patients 
with severe disease) [29]. 
 Fig.  (2) [29] shows both treatment of acute exacerbations 
(using short-acting bronchodilators (example in Table 2) [5, 
23, 30] and other agents to prevent relapse and 
rehospitalization) and post-exacerbation management (using 
maintenance pharmacotherapies (examples in Table 2) [5, 
23, 30] and non-pharmacologic strategies to prevent future 
exacerbations and interrupt pulmonary decline). 
Acute Exacerbations 
  Increasing the dose and frequency of short-acting 
bronchodilators is a necessary first step in the treatment of 
acute exacerbations, with the addition of oral corticosteroids 
for individuals unresponsive to the first intervention [29]. 
Changes in sputum characteristics may necessitate the 
addition of antibiotics appropriate to the causative bacterial 
pathogen (e.g. anti-pseudomonal -lactams may be needed if 
Pseudomonas spp. are present, as is sometimes the case with 
severe exacerbations) [5]. However, it should be noted that 
in many cases the etiology cannot be confirmed, due to 
colonization, and thus even when bacteria are cultured from 
samples, this may not prove to be beneficial prior to 
initiating treatment. However, when a causative organism 
can be identified, individual, local and regional antibiotic-
Table 1.  Disease Staging and General Symptoms
a 
 
Stage FEV1/FVC FEV1 Predicted  General COPD Symptoms 
I (mild)  <0.7  80%  Chronic cough or sputum production may be present (but not always) 
II (moderate)  <0.7  50% FEV1 <80%  Exertional dyspnea develops (cough and sputum production sometimes 
present); some patients may have frequent exacerbations 
III (severe)  <0.7  30% FEV1 <50%  Greater exertional dyspnea, fatigue and repeated exacerbations 
IV (very severe)  <0.7  FEV1 <30% or 50% predicted plus 
chronic respiratory failure 
Symptoms worsen; potentially life-threatening exacerbations 
FEV1=forced expiratory volume in 1 second; FVC=forced vital capacity; COPD=chronic obstructive pulmonary disease. 
aPlease refer to reference [5] as cited in text. 16    The Open Nursing Journal, 2012, Volume 6  Garvey and Ortiz 
resistance patterns, as well as drug availability, side effects 
and treatment duration are important considerations in the 
selection of an antibiotic [5, 29]. Thus far, the prophylactic 
use of antibiotics for prevention of exacerbations has not 
been tested in real-world settings. Additional interventions, 
such as theophylline, may be required in selected cases 
where the clinical response to treatment is incomplete [29]. 
However, the use of theophylline is subject to the need for 
close monitoring of serum levels because of known side 
effects and pharmacokinetic interactions with other 
medication. An increased dosage may be required in patients 
who continue to smoke and in patients taking medications 
that are eliminated hepatically. A dosage reduction is 
necessary in patients with hepatic failure or congestive heart 
failure, and in those patients receiving, among other 
medications, macrolide antibiotics, quinolone antibiotics, 
allopurinol, oral contraceptives, and histamine H2-receptor 
blocking agents [31]. Furthermore, monitoring serum 
theophylline levels following dosage adjustment is important 
for maintenance of a therapeutic drug level. 
  Criteria listed in Table 3 [5] are grounds for prompt 
admission to the hospital or intensive care unit, where local 
resources regarding personnel, skills and equipment for 
managing acute respiratory failure are available. 
Supplemental oxygen therapy is necessary at any stage in the 
presence of new or established hypoxemia and/or respiratory 
failure (Fig. 2) [29], with a goal of improving baseline blood 
oxygenation to a partial pressure level of at least 60 mm Hg 
at sea level and to produce a saturation level of oxygen of at 
least 90% for an uncomplicated exacerbation [5]. Non-
invasive positive pressure ventilation is considered to be 
effective in reversing acute respiratory failure in selected 
patients with elevated carbon dioxide and no other life-
threatening comorbidities who are able to cooperate with 
healthcare providers [22]. A need for oxygen and/or 
ventilatory support, premature onset (aged <40 years) or 
severe disease, precipitous health decline and new 
comorbidities (Fig. 2) [29] are all reasons for referring 
patients to a specialist [22]. 
PREVENTION OF FUTURE EXACERBATIONS 
  Although long-term, multifaceted care is a goal for all 
patients with COPD, it is of particular importance to those 
who have recovered from acute exacerbations. To prevent 
relapse, the GOLD guidelines [5] suggest spirometric 
evaluations 4-6 weeks after hospitalization for an acute 
exacerbation; however, the utility of these results in terms of 
modifying therapy awaits evaluation in randomized, 
controlled trials. Generally, risk-reduction measures (e.g. 
smoking cessation counseling and appropriate vaccinations), 
maintenance pharmacotherapies, PR and self-management 
support form the key components of long-term management 
to prevent future exacerbations. Self management plans for 
COPD are available at: http://www.lunguk.org/supporting-
you/Publications/copd_self_management_plan and http://ww 
w.livingwellwithcopd.com/ password is copd. 
  Clinicians should understand principles of collaborative 
disease self management. Of significant importance in COPD is 
working with the patient and medical team to support long-term 
smoking cessation, influenza and pneumococcal vaccination, 
effective use of optimal medication, such as long-acting 
bronchodilators, patient understanding of prevention, and 
prompt reporting of symptoms suggestive of exacerbation or 
lung infection and regular clinician follow-up. 
 Approved  long-acting  -agonists (LABAs) or long-acting 
anticholinergics (LAACs), administered individually or in 
combination therapies (Table 2) [5, 23, 30], have been 
 
Reproduced with permission from Biomed Central, http://creativecommons.org/licenses/by/3.0/).
 
aPlease refer to reference [29] as cited in text. 
Fig. (2). Treatment algorithm for exacerbations.
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shown to be effective for the maintenance treatment of stable 
COPD. Together with results from two separate megatrials 
[23, 30], the exacerbation-reducing benefits of the 
LABA/inhaled corticosteroid combination, salmeterol/fluti-
casone, and the LAAC, tiotropium, suggest that these 
medications can reduce disease progression. More precisely, 
salmeterol/fluticasone and tiotropium can potentially dec-
rease exacerbation frequency or prevent future exacerbat-
ions, thereby reducing the need for healthcare utilization. 
  In addition, PR, including patient education on disease 
self-management strategies and monitored, supervised 
exercise, has been shown to improve dyspnea, exercise 
capacity and quality of life, and has been shown to reduce 
healthcare utilization in persons with chronic lung disease.  
 
There is emerging evidence regarding the role of PR in 
patients recovering from an acute event, particularly if 
sustained over the long-term [5]. 
 Self-management plans, whether independently 
administered or incorporated as part of PR (e.g. physician-
directed action plan, including prescriptions of relevant 
medications and strategies for optimizing daily activities), 
empower patients to recognize symptoms and provide a 
guide as to appropriate next steps. Regardless of the 
established long-term plan, patients should be examined 
within at least four weeks following hospital discharge [22]. 
  The goals of the initial follow-up and regular treatment 
reviews are primarily to monitor disease progression, 
symptoms and overall health status of the patient (Table 4) 
[5]. However, regular provider—patient meetings also   
Table 2.  Examples of COPD Pharmacotherapies
a 
 
Drug Class (Example)  Recommended Purpose (Drug Class) 
Increase Dose and/or Frequency for Acute Exacerbations 
Short-acting 2-agonist 
•  Albuterol  
Can be used during all stages of the disease 
Long-Acting Agents (for prevention of future exacerbations) 
LABA 
•  Formoterol 
•  Arfomoterol 
•  Salmeterol  




Maintenance therapy beginning in GOLD II; more effective than short-acting agents alone 
LABA/inhaled corticosteroid combinations 
•  Salmeterol/Fluticasone
2 
Can be used for the treatment of patients with severe and very severe COPD 
1Indicated to reduce exacerbations. 
2Indicated to reduce exacerbations in COPD patients with a history of exacerbations. 
LABA=Long-acting 2-agonist; GOLD II=Global Initiative for Chronic Obstructive Lung Disease stage II (moderate COPD); COPD=chronic obstructive pulmonary disease. 
aPlease refer to references [5, 23, 30] as cited in text. 
 





•  Advanced age or very little family/home support 
•  Uncertain diagnosis 
•  Severe disease/increased severity or frequency of symptoms 
•  Development of new symptoms, such as peripheral edema and cyanosis 
•  Significant comorbidities 
•  Newly occurring arrhythmias 
ICU Admission 
•  Severe breathlessness, unresponsive to initial therapy 
•  Confusion, lethargy, coma or other changes in mental status 
•  Hypercapnia, respiratory acidosis or worsening hypoxemia despite appropriate interventions 
•  Requirement for invasive mechanical ventilation 
•  Hemodynamic instability, e.g. tachycardia, arrhythmias or hypotension 
1Local resources should be considered. 
ICU=intensive care unit. 
aPlease refer to reference [5] as cited in text. 18    The Open Nursing Journal, 2012, Volume 6  Garvey and Ortiz 
present opportunities for the NP/PA to establish a rapport 
with patients and better understand their personal and health-
related goals. It has been established that treatment plans 
incorporating, for example, individualized diet and exercise 
programs; education around pharmacotherapies, disease, 
inhalation techniques [32] and relaxation practices, can 
improve the mental and physical well-being of patients. 
Regular follow-up also allows the healthcare practitioner to 
note early signs of exacerbations and educate patients about 
the importance of symptom reporting (e.g. as part of a self-
management plan) and self-management. 
ROLE OF NPs AND PAs 
  The management of COPD exacerbations is variable in 
critical [33] and primary care [34] settings, in spite of 
recommendations from major respiratory guidelines [5, 22]. 
Delegating collaborative patient evaluation, management and 
follow-up in an orchestrated manner by NPs and PAs in 
these settings may improve the consistency and quality of 
care in patients who are prone to or experiencing an 
exacerbation. Historically, supervised NPs and PAs have 
provided similar quality of emergency care to patients with 
acute respiratory disease as physicians have provided [35]. A 
vital part of expanding NP and PA involvement in all aspects 
of exacerbation management is to increase their knowledge 
base, the positive effects of which are shown in the results 
from the Stemming the Tide of Antibiotic Resistance 
(STARS) [36] educational initiative, which included NPs as 
participants. In addition, Sridhar et al., [37] reported that 
nurse-led care for patients who were hospitalized with an 
acute exacerbation, including PR, self-management 
education and an action plan, resulted in reduced primary 




  Expanded knowledge of treatment components could 
positively affect healthcare-provider management, and 
prescribing practices and attitudes in the treatment of 
exacerbations of COPD. Further studies are needed to assess 
the impact of real-world interventions involving NPs and 
PAs on preventing or delaying exacerbation recurrence in 
patients following recovery from an index event. 
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